Department of Pharmacology, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Pharmacy of Tongji Hospital, Tongji Medical College, Huazhong Science and Technology University, Wuhan, China.
Front Immunol. 2022 May 12;13:897356. doi: 10.3389/fimmu.2022.897356. eCollection 2022.
Interleukin-33 (IL-33) belongs to the interleukin-1 (IL-1) family, and its structure is similar to IL-18. When cells are damaged or undergo necrosis, mature form of IL-33 is secreted as a cytokine, which can activate the immune system and provide danger signals. The IL-33/ST2 signaling pathway is composed of IL-33, suppression of tumorigenicity 2 (ST2), and IL-1 receptor accessory protein (IL-1RAcP). IL-33 has been reported to be strongly associated with lung cancer progression, and can exhibit opposite effects on lung cancer under different conditions. In this review, we have summarized the structure and basic functions of IL-33, its possible function in immune regulation, and its role in pulmonary fibrosis as well as in lung cancer. We have highlighted the dual regulation of IL-33 in lung cancer and proposed potential lung cancer treatment regimens, especially new immunotherapies, based on its mechanism of action.
白细胞介素-33(IL-33)属于白细胞介素-1(IL-1)家族,其结构类似于白细胞介素-18。当细胞受损或发生坏死时,IL-33 以成熟形式作为细胞因子被分泌出来,从而激活免疫系统并提供危险信号。IL-33/ST2 信号通路由 IL-33、肿瘤抑制因子 2(ST2)和白细胞介素-1 受体辅助蛋白(IL-1RAcP)组成。已有研究报道称,IL-33 与肺癌的进展密切相关,并且在不同条件下对肺癌可能产生相反的作用。在本综述中,我们总结了 IL-33 的结构和基本功能、其在免疫调节中的可能作用,以及其在肺纤维化和肺癌中的作用。我们强调了 IL-33 在肺癌中的双重调节作用,并根据其作用机制提出了潜在的肺癌治疗方案,特别是新的免疫疗法。